Company: PSTV
Filing Date: 2025-06-18
Form Type: S-1
Source: 0001193125-25-142215
Chunk: 6

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-06-18
Form: S-1
Chunk 6
---
ement Date in accordance with the Purchase Agreement. |

| Shares of our common stock outstanding prior to this offering (as of June 17, 2025) | 50,998,468 shares of our common stock. |

| Shares of our common stock to be outstanding after this offering | 67,998,468 shares of our common stock, assuming the sale of all the shares of common stock registered hereunder to Lincoln Park under the Purchase Agreement. The actual number of shares outstanding after this offering will vary depending upon 
 the actual number of shares we sell to Lincoln Park under the Purchase Agreement after the date of this prospectus.                                                                                                                                |

| Use of proceeds | We will receive no proceeds from the sale of shares of our common stock by Lincoln Park in this offering. We may receive up to $50.0 million aggregate gross proceeds under the Purchase Agreement from any sales of shares of our common stock         
 we make to Lincoln Park pursuant to the Purchase Agreement, assuming that we sell the full amount of our common stock that we have the right, but not the obligation to sell to Lincoln Park under the Purchase Agreement. Any proceeds that we receive 
 from sales of shares of our common stock to Lincoln Park under the Purchase Agreement will be used for working capital and general corporate purposes. See “Use of Proceeds.”                                                                           |

| Nasdaq symbol for our common stock | “PSTV” |

| Risk factors | This investment involves a high degree of risk. See “Risk Factors” beginning on page 3 of this prospectus for a discussion of factors you should carefully consider before deciding to invest in our securities. |

Unless otherwise noted, the number of shares of common stock to be outstanding immediately after this offering is based on 50,998,468 shares outstanding as of June 17, 2025 and excludes, as of June 17, 2025:

| • |     | 1,230,272 shares of common stock issuable upon exercise of stock options outstanding under our equity incentive 
 plans, with a weighted-average exercise price of $3.79 per share;                                               |

| • |     | 7,668 shares of common stock reserved for future issuance under our 2015 New Employee Incentive Plan; |

| • |     | 1,222,604 shares of common stock reserved for future issuance under our 2020 Stock Incentive Plan; |

| • |     | 398 and 27,792 shares of common stock issuable upon conversion of 1,014 shares of